Presentation is loading. Please wait.

Presentation is loading. Please wait.

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin.

Published byShana Andrews Modified over 6 years ago

Similar presentations

Presentation on theme: "Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin."— Presentation transcript:

1 Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin Schartz, MD, PhD, Sylvie Chevret, MD, PhD, Carolina Paz, MD, Delphine Kerob, MD, Olivier Verola, MD, Patrice Morel, MD, Céleste Lebbé, MD, PhD  Journal of the American Academy of Dermatology  Volume 58, Issue 4, Pages (April 2008) DOI: /j.jaad Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 At 36 weeks, 5 (29%) of 17 patients achieved overall clinical response (complete and partial) evaluated on basis of tumor area (A) and 11 (65%) achieved overall clinical response on basis of infiltration score (B). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 At 36 weeks, 22 (24%) of 90 lesions achieved overall clinical response (complete and partial) evaluated on basis of tumor area (A) and 48 (53%) achieved overall clinical response on basis of infiltration score (B). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Biopsy-proven nodular Kaposi's sarcoma lesions of thumb in Caucasian man before (A) and after (B) 24 weeks of imiquimod treatment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Papular Kaposi's sarcoma lesions of thenar eminence in black man before (A) and after (B) 24 weeks of imiquimod treatment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 Multiple papular Kaposi's sarcoma lesions on ankle of Caucasian woman before (A) and after (B) 24 weeks of imiquimod treatment. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients  Noël Emile Célestin."

Similar presentations

Tianyou Wang, MD, Xiaoxi Lin, MD, PhD, Yunbo Jin, MD, PhD, Xi Yang, MD 

Tianyou Wang, MD, Xiaoxi Lin, MD, PhD, Yunbo Jin, MD, PhD, Xi Yang, MD 
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC)  Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing,

Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC)  Péter Holló, MD, PhD, Hajnalka Jókai, MD, PhD, Judit Hársing,
Clavi syphilitici–an unusual presentation of syphilis

Clavi syphilitici–an unusual presentation of syphilis
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Striking leflunomide efficacy against refractory cutaneous sarcoidosis

Striking leflunomide efficacy against refractory cutaneous sarcoidosis
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Accuracy of biopsy sampling for subtyping basal cell carcinoma

Accuracy of biopsy sampling for subtyping basal cell carcinoma
Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD 

Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD 
Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD 
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti–tumor necrosis factor-alfa agents  Julie Caron, MD, Carine Michot,

Aggressive cutaneous infection with Mycobacterium marinum in two patients receiving anti–tumor necrosis factor-alfa agents  Julie Caron, MD, Carine Michot,
Tianyou Wang, MD, Xiaoxi Lin, MD, PhD, Yunbo Jin, MD, PhD, Xi Yang, MD 

Tianyou Wang, MD, Xiaoxi Lin, MD, PhD, Yunbo Jin, MD, PhD, Xi Yang, MD 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
The diagnostic accuracy of in vivo confocal microscopy in clinical practice  Danielle Giambrone, BS, Mahin Alamgir, MD, Aisha Masud, BS, Tara Bronsnick,

The diagnostic accuracy of in vivo confocal microscopy in clinical practice  Danielle Giambrone, BS, Mahin Alamgir, MD, Aisha Masud, BS, Tara Bronsnick,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Similar presentations

Ads by Google